 |
 Video: What is a Stock Split?
|
|
|
| MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer cells. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells and suppress Graft versus Host Disease. According to our INKT split history records, MiNK Therapeutics has had 2 splits. | |
|
MiNK Therapeutics (INKT) has 2 splits in our INKT split history database. The first split for INKT took place on January 28, 1999. This was a 2 for 1
split, meaning for each share of INKT owned pre-split, the shareholder now owned 2 shares. For example, a 1000 share position pre-split, became a 2000 share position following the split. INKT's second split took place on December 31, 1999. This was a 2 for 1
split, meaning for each share of INKT owned pre-split, the shareholder now owned 2 shares. For example, a 2000 share position pre-split, became a 4000 share position following the split.
When a company such as MiNK Therapeutics splits its shares, the market capitalization before and after the split takes place remains stable, meaning the shareholder now owns more shares but each are valued at a lower price per share. Often, however, a lower priced stock on a per-share basis can attract a wider range of buyers. If that increased demand causes the share price to appreciate, then the total market capitalization rises post-split. This does not always happen, however, often depending on the underlying fundamentals of the business.
Looking at the INKT split history from start to finish, an original position size of 1000 shares would have turned into 4000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into MiNK Therapeutics shares, starting with a $10,000 purchase of INKT, presented on a split-history-adjusted basis factoring in the complete INKT split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
10/18/2021 |
|
| End date: |
12/10/2025 |
|
| Start price/share: |
$11.70 |
|
| End price/share: |
$12.74 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
8.89% |
|
| Average Annual Total Return: |
2.07% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$10,887.02 |
|
| Years: |
4.15 |
|
|
|
| Date |
Ratio |
| 01/28/1999 | 2 for 1
| | 12/31/1999 | 2 for 1
|
|
|
Free INKT Email Alerts:
